• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: March 2022

Pharma & Human Health

Researchers identify potential approaches to modify the vaginal microbiome

March 30, 2022 Microbiome Times

The female genital tract is naturally colonized by mixed communities of bacteria, known as the vaginal microbiome. When these communities are dominated by species such as Lactobacillus crispatus, they provide important protective functions in genital health. […]

Finance

How insights from the field of advanced therapy medicinal products (ATMPs) can inform solutions in the microbiome field

March 23, 2022 Microbiome Times

Upcoming panel at Pharmabiotics Conference & Partnering 2022 will explore what microbiome drug developers can learn from another area of pharmaceutical innovation Live Biotherapeutic Products (LBPs) emerging from microbiome-related scientific innovation are novel and exciting […]

Pharma & Human Health

A new photoactive viral vector for anti-cancer therapy has been developed

March 15, 2022 Microbiome Times

A research team at the University of Bologna has developed a new targeted cancer therapy based on the action of a genetically modified phage, a virus that infects bacteria. The study made the cover of […]

Finance

Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia

March 14, 2022 Microbiome Times

Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, and BIOASTER, the first Institute for Technological Innovation in Microbiology, announce the implementation of research collaboration to use […]

Pharma & Human Health

Deciphering gut microbiome ‘chatter’ to combat IBD

March 14, 2022 Microbiome Times

Scientists at the Earlham Institute, Quadram Institute and University of East Anglia on the Norwich Research Park, have developed a new computational biology method to better understand IBD for targeted clinical treatments. By analysing specific […]

Finance

SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark

March 9, 2022 Microbiome Times

SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern […]

Finance

Microbiotica raises $67M to advance pipeline of microbiome-based therapeutics

March 9, 2022 Microbiome Times

Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
  • Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet
    April 3, 2025
  • Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
    March 25, 2025
  • Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis
    March 5, 2025
sign up

Sign up to the Microbiome Times newsletter